Format

Send to

Choose Destination
Protein Pept Lett. 2017;24(4):340-347. doi: 10.2174/0929866524666170209153421.

When Good Goes Awry: The Aggregation of Protein Therapeutics.

Author information

1
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612. United States.
2
USF Health Byrd Alzheimer`s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612. United States.
3
Department of Molecular Medicine Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., MDC07, Tampa, Florida 33612. United States.

Abstract

Protein therapeutics are playing an increasingly important role in treatment of a variety of human diseases. However, like the rest of proteins, they are susceptible to aggregation. Aggregation of proteinaceous pharmaceuticals can cause a loss of efficacy and, potentially, cytotoxicity and an immunogenic response. This review describes various ways protein therapeutics aggregate and a variety of approaches taken to prevent or minimize this process.

KEYWORDS:

Aggregation; antibodies; delivery; formulation; glucagon; insulin; storage

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center